A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

ABT-199: Taking Dead Aim at BCL-2

(2013) Matthew S. Davids et al.   CANCER CELL

Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes

(2013) F Basit et al.   CELL DEATH AND DIFFERENTIATION

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Bcl-xL-inhibitory BH3 mimetics (ABT-737 or ABT-263) and the modulation of cytosolic calcium flux and platelet function

(2012) S. M. Schoenwaelder et al.   BLOOD

Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumoursin vivo

(2012) S Ackler et al.   BRITISH JOURNAL OF PHARMACOLOGY

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

(2012) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

620 A Study of PNT2258 (DNA-targeted Blocker of BCL2 Expression) in Patients with Advanced Solid Tumors

(2012) D.W. Rasco et al.   EUROPEAN JOURNAL OF CANCER

Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines

(2012) Abid R. Mattoo et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer

(2012) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Navitoclax (ABT-263) Reduces Bcl-xL-Mediated Chemoresistance in Ovarian Cancer Models

(2012) M. Wong et al.   MOLECULAR CANCER THERAPEUTICS

The accessible chromatin landscape of the human genome

(2012) Robert E. Thurman et al.   NATURE

Target mRNA inhibition by oligonucleotide drugs in man

(2012) H. L. Lightfoot et al.   NUCLEIC ACIDS RESEARCH

The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein

(2011) Meike Vogler et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Navitoclax (ABT-263) Accelerates Apoptosis during Drug-Induced Mitotic Arrest by Antagonizing Bcl-xL

(2011) J. Shi et al.   CANCER RESEARCH

Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models

(2011) Nguyen Tan et al.   CLINICAL CANCER RESEARCH

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

From Mitochondrial Biology to Magic Bullet: Navitoclax Disarms BCL-2 in Chronic Lymphocytic Leukemia

(2011) Loren D. Walensky   JOURNAL OF CLINICAL ONCOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

(2011) J. Chen et al.   MOLECULAR CANCER THERAPEUTICS

An Amino Acid-based Amphoteric Liposomal Delivery System for Systemic Administration of siRNA

(2011) Roger C Adami et al.   MOLECULAR THERAPY

RNAi-based Therapeutics Targeting Survivin and PLK1 for Treatment of Bladder Cancer

(2011) Shaguna Seth et al.   MOLECULAR THERAPY

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis

(2010) Sakuma   ONCOLOGY REPORTS

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH